|0.0812 0 (0%)||12-20 16:00|
|Targets||6-month :||0.15||1-year :||0.19|
|Resists||First :||0.13||Second :||0.16|
|Supports||First :||0.07||Second :||0.05|
|MAs||MA(5) :||0.08||MA(20) :||0.1|
|MA(100) :||0.45||MA(250) :||1.11|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||10.5||D(3) :||9.2|
|52-week||High :||3.25||Low :||0.04|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLVS ] has closed above bottom band by 6.4%. Bollinger Bands are 80.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||0.09 - 0.09||0.09 - 0.09|
|Low:||0.07 - 0.07||0.07 - 0.07|
|Close:||0.07 - 0.08||0.08 - 0.08|
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||145 (M)|
|Shares Float||143 (M)|
|Held by Insiders||1.4 (%)|
|Held by Institutions||25.8 (%)|
|Shares Short||28,490 (K)|
|Shares Short P.Month||30,770 (K)|
|EPS Est Next Qtrly||-1.15|
|EPS Est This Year||-7.58|
|EPS Est Next Year||-2.47|
|Book Value (p.s.)||-2.9|
|Profit Margin||-189.4 %|
|Operating Margin||-155.2 %|
|Return on Assets (ttm)||-30.2 %|
|Return on Equity (ttm)||0 %|
|Qtrly Rev. Growth||-19.2 %|
|Gross Profit (p.s.)||0.79|
|Sales Per Share||0.91|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-176 (M)|
|Levered Free Cash Flow||-128 (M)|
|Price to Book value||-0.03|
|Price to Sales||0.08|
|Price to Cash Flow||-0.07|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|